| Bioactivity | Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects[1]. |
| Invitro | Osocimab (1.4 nM-1 μM；30 分钟) 抑制凝血酶生成，同时抑制人血浆中 FXIa 介导的 FIX 激活 (或 FIX 转化) (IC50=16 nM) 和 FXIa 介导的底物裂解 (IC50=1.2 nM)[1]。Osocimab (22.05 mg/mL) 抑制内在通路介导的凝血级联激活[1]。 |
| Name | Osocimab |
| CAS | 2056878-75-0 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Schaefer M, et al. Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI. J Mol Biol. 2019 Dec 6;431(24):4817-4833. |